Free Trial
NASDAQ:CARM

Carisma Therapeutics (CARM) Stock Price, News & Analysis

Carisma Therapeutics logo
$0.26 +0.01 (+2.50%)
Closing price 10/7/2025 04:00 PM Eastern
Extended Trading
$0.26 -0.01 (-2.44%)
As of 10/7/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Carisma Therapeutics Stock (NASDAQ:CARM)

Advanced

Key Stats

Today's Range
$0.25
$0.27
50-Day Range
$0.22
$0.44
52-Week Range
$0.14
$1.27
Volume
1.15 million shs
Average Volume
1.24 million shs
Market Capitalization
$10.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.93
Consensus Rating
Moderate Buy

Company Overview

Carisma Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

CARM MarketRank™: 

Carisma Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 572nd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Carisma Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 4 hold ratings, and 1 sell rating.

  • Upside Potential

    Carisma Therapeutics has a consensus price target of $1.93, representing about 633.6% upside from its current price of $0.26.

  • Amount of Analyst Coverage

    Carisma Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Carisma Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Carisma Therapeutics are expected to grow in the coming year, from ($1.32) to ($1.26) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Carisma Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Carisma Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Carisma Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    6.40% of the float of Carisma Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Carisma Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Carisma Therapeutics has recently increased by 99.37%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Carisma Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Carisma Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.40% of the float of Carisma Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Carisma Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Carisma Therapeutics has recently increased by 99.37%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Carisma Therapeutics has a news sentiment score of -0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Carisma Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    25 people have searched for CARM on MarketBeat in the last 30 days. This is an increase of 733% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Carisma Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Carisma Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $123,930.00 in company stock.

  • Percentage Held by Insiders

    Only 6.90% of the stock of Carisma Therapeutics is held by insiders.

  • Percentage Held by Institutions

    44.27% of the stock of Carisma Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Carisma Therapeutics' insider trading history.
Receive CARM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CARM Stock News Headlines

URGENT: The Market's 3 Red Flags Are Flashing
The warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gold price (signaling fear), and escalating geopolitical risk. A sharp correction might happen tomorrow, and most investors will be caught off guard. Your portfolio is currently exposed.tc pixel
Carisma Therapeutics Amends Agreement with Moderna
Carisma Therapeutics Approves Reverse Stock Split
See More Headlines

CARM Stock Analysis - Frequently Asked Questions

Carisma Therapeutics' stock was trading at $0.4188 at the start of the year. Since then, CARM stock has decreased by 37.3% and is now trading at $0.2624.

Carisma Therapeutics Inc. (NASDAQ:CARM) released its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.05. The company earned $3.65 million during the quarter, compared to analyst estimates of $2.47 million.

Shares of CARM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Carisma Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
5/13/2025
Today
10/07/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CARM
CIK
1485003
Web
N/A
Employees
20
Year Founded
2016

Price Target and Rating

High Price Target
$5.00
Low Price Target
$0.70
Potential Upside/Downside
+633.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$60.48 million
Net Margins
-254.28%
Pretax Margin
-458.60%
Return on Equity
N/A
Return on Assets
-192.17%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.48
Quick Ratio
0.48

Sales & Book Value

Annual Sales
$10.77 million
Price / Sales
1.02
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.67) per share
Price / Book
-0.39

Miscellaneous

Outstanding Shares
41,788,000
Free Float
38,905,000
Market Cap
$10.97 million
Optionable
No Data
Beta
2.06

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:CARM) was last updated on 10/8/2025 by MarketBeat.com Staff
From Our Partners